GLP-1
44 quarters of ground truth.
This is what IMX Data sees — and what it means for you.
Press arrow keys, space, or Enter to advance
Aggregated averages hide critical variation in state-by-state adoption, spend, and payer mix.
By the time public data surfaces, the market has moved. Competitors have already repositioned.
Piecing together demographics, drug mix, and geography means months of reconciliation with no single truth.
The GLP-1 market grew 3,497% in a decade. Every quarter you operate without granular claims intelligence, you're navigating the fastest-growing drug market in history — blindfolded.
The spend story is as dramatic as the claims story — but the composition matters. Plan pay has surged while patient out-of-pocket compresses, reflecting insurer adoption waves and manufacturer coupon programs.
The signal: When patient OOP flattens while plan pay accelerates, it marks an insurer coverage wave — visible in IMX data quarters before analyst reports catch up.
IMX aggregates, normalizes, and delivers U.S. pharmaceutical claims at a depth no other provider matches — state-level, quarter-by-quarter, segmented by drug, payer, demographics, and geography.
All 50 U.S. states. Real prescribing behavior, state by state, every quarter — not national averages.
2015–2025. Every inflection point, every policy shock, every drug launch is visible in the data.
Ozempic vs. Wegovy vs. Mounjaro vs. Zepbound — claims, spend, and share broken out by drug.
Medicare, Medicaid, PBM, Commercial, Cash — each tracked separately, every single quarter.
Age cohorts, gender — every dimension needed to model real patient populations with precision.
National averages mask enormous state-to-state variation. IMX Data delivers prescribing intelligence at the state level (even as granular as Zip level) — identify where adoption is accelerating, where payers are resisting, where the next opportunity is forming.
Real insight: When Zepbound received FDA approval, IMX Data revealed which states adopted within the first quarter vs. those lagging 6+ months — exposing physician network dynamics invisible nationally.
50 states tracked. Every adoption curve, every payer shift — visible as it happens.
IMX tracks every drug on a daily basis. When SURMOUNT-5 showed Zepbound 20.2% vs Wegovy 13.7% weight loss (NEJM, Jan 2025), Zepbound surpassed Wegovy in total claims by Q1 2025 — visible in IMX data the very quarter of publication.
IMX Data separates Medicare, Medicaid, Commercial, PBM, and Cash-pay volumes. The cash-pay segment alone tells you more about pricing strategy than any analyst report.
98.7% of spend is covered by payers — but the cash-pay trajectory is the most direct signal for oral GLP-1 pricing. IMX tracks it daily.
The 1960s birth decade leads with 5.0M claims — the highest-volume segment. Oral GLP-1 penetration into younger cohorts is the #1 thesis to validate in upcoming quarters.
The company Novo Nordisk believes its newly launched oral version of Wegovy can expand treatment to groups that have so far been under-represented in GLP-1 use, particularly men and younger patients. This can be verified with IMX data.
Why it matters: Oral semaglutide targets cash-pay, younger, male patients — all trackable in IMX breakdowns. First signs of market expansion appear here.
IMX Data is the early warning system. Every policy shift, every approval, every pricing change — you'll see its footprint in claims data before it becomes consensus. 44 quarters of proof.
IMX Data delivers the depth behind the headlines.
Every drug · Every state · Every day.